Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The management of Spencer Pharmaceutical Inc. is delighted to announce the addition of Dr. Merzouki to the Scientific Advisory Board. He brings a wealth of scientific research knowledge to the team. Dr. Merzouki is a research scientist and professor of Virology-Immunology.
He is currently teaching and lecturing at the Institute of Biomedical Engineering (Department of Chemical Engineering) at Ecole Polytechnique de Montreal since 2007 as a senior scientist where he currently manages a suite of molecular and cell biology laboratories.
About ItsAllBull.net:
Itsallbull.net is an online financial community forum aimed at providing financial information to money managers, individual investors and analysts. They offer a unique information service to the investment communities by offering Technical analysis and Corporate videos, Reports and Presentations, Corporate Governance on over 29,000 publicly Traded Companies. At its creation date on September 1, 2009, the IAB MCSC Index initially selected 2000 companies from the total number of equities listed on the above mentioned exchanges to include in the Index. Criteria used to select the Index component companies included; companies having a stock price of no more than $5.00, and stocks experiencing at least a minimal level of daily trading volume. Then for each stock selected for the MCSC Index portfolio, an initial position worth $10,000 USD was recorded. The IAB MCSC Index is reviewed and updated daily, and equities that no longer meet the inclusion criteria are removed and/or replaced. As delisting and name/symbol changes are common within the realm of the OTC markets, the actual number of equities listed in the MCSC Index will change frequently, and at any particular time may be less than 2000. Currently, the MCSC Index employs 1843 component companies.
i think this audio was pretty important on knowing their plan and structure of whats going on.
You can view its performance at http://www.itsallbull.net/mcsc.php
i agree, greens do come up and i think soon we will see them stay soon in the future
so far the company has been holding their values and pr's give us the edge to runs but taking it steady, patients is most important in this situation. imo
Volume: 161,833 @ 11:31:33 AM ET
Bid Ask Day's Range
0.28 0.304 0.27 - 0.345
About Spencer Pharmaceutical Inc.
Spencer Pharmaceutical Inc. is a US based Pharmaceutical Research and Development Corporation, which is developing innovative drug release and absorption systems for the treatment of metabolic diseases such as diabetes and metabolic syndrome
According to the mandate, the independent laboratory will perform the animal testing to validate the release time and efficiency of the new Spencer met4 formulation.
"Management believes that the independent laboratory will significantly increase the visibility of Spencer. These tests are straightforward and can be accomplished over the next month or so," stated Dr. Max Arella, President of Spencer Pharmaceutical Inc. Furthermore, "Tests are not only necessary but may help us in adding value to future licensing deals and can potentially provide significant revenue stream for the company in the near and long term while creating significant share hold value."
we still have the potential for a move.
He is currently teaching and lecturing at the Institute of Biomedical Engineering (Department of Chemical Engineering) at Ecole Polytechnique de Montreal since 2007 as a senior scientist where he currently manages a suite of molecular and cell biology laboratories.
"Dr. Merzouki is a molecular biologist and an immunologist with a long experience in the gene therapy area where he has performed several preclinical and clinical analysis for pharmaceutical companies involving the use of adenoviral vectors for cancer (Introgen Therapeutics Inc., USA Gencell Asia/Pacific, Japan) and DNA plasmid vectors for peripheral artery occlusive disease (Aventis Pharma, France/USA). Dr. Merzouki has an extensive expertise in the design of expressing vectors, production and purification of recombinants proteins. He developed technologies (Patents pending) for production of biogeneric therapeutic proteins for the treatment of various diseases including cancer, diabetes, hepatitis or multiple sclerosis," stated Dr. Max Arella, CEO and Chairman of Spencer Pharmaceutical Inc. "We are pleased that Dr. Merzouki has accepted to serve Spencer Pharmaceutical as a scientific and business advisor. His extensive network in scientific and businesses circles in the Middle East/North Africa regions will certainly be a major asset for our company in future negotiations in this part of the world," concluded Dr. Arella.
About Spencer Pharmaceutical Inc.
Spencer Pharmaceutical Inc. is a US based Pharmaceutical Research and Development Corporation, which is developing innovative drug release and absorption systems for the treatment of metabolic diseases such as diabetes and metabolic syndrome.
Important Information
volume grew bigg time here, support id looking solid.
SPPH :
BOSTON, MA--(Marketwire - 10/28/10) - Spencer Pharmaceutical Inc. (Pinksheets:SPPH - News) announced today the addition of Dr. Abderrazzak Merzouki to join its Scientific Advisory Board as well as accepting a position as a business advisor with the company.
The management of Spencer Pharmaceutical Inc. is delighted to announce the addition of Dr. Merzouki to the Scientific Advisory Board. He brings a wealth of scientific research knowledge to the team. Dr. Merzouki is a research scientist and professor of Virology-Immunology.
He is currently teaching and lecturing at the Institute of Biomedical Engineering (Department of Chemical Engineering) at Ecole Polytechnique de Montreal since 2007 as a senior scientist where he currently manages a suite of molecular and cell biology laboratories.
"Dr. Merzouki is a molecular biologist and an immunologist with a long experience in the gene therapy area where he has performed several preclinical and clinical analysis for pharmaceutical companies involving the use of adenoviral vectors for cancer (Introgen Therapeutics Inc., USA Gencell Asia/Pacific, Japan) and DNA plasmid vectors for peripheral artery occlusive disease (Aventis Pharma, France/USA). Dr. Merzouki has an extensive expertise in the design of expressing vectors, production and purification of recombinants proteins. He developed technologies (Patents pending) for production of biogeneric therapeutic proteins for the treatment of various diseases including cancer, diabetes, hepatitis or multiple sclerosis," stated Dr. Max Arella, CEO and Chairman of Spencer Pharmaceutical Inc. "We are pleased that Dr. Merzouki has accepted to serve Spencer Pharmaceutical as a scientific and business advisor. His extensive network in scientific and businesses circles in the Middle East/North Africa regions will certainly be a major asset for our company in future negotiations in this part of the world," concluded Dr. Arella.
About Spencer Pharmaceutical Inc.
Spencer Pharmaceutical Inc. is a US based Pharmaceutical Research and Development Corporation, which is developing innovative drug release and absorption systems for the treatment of metabolic diseases such as diabetes and metabolic syndrome.
SPPH :
He is currently teaching and lecturing at the Institute of Biomedical Engineering (Department of Chemical Engineering) at Ecole Polytechnique de Montreal since 2007 as a senior scientist where he currently manages a suite of molecular and cell biology laboratories.
"Dr. Merzouki is a molecular biologist and an immunologist with a long experience in the gene therapy area where he has performed several preclinical and clinical analysis for pharmaceutical companies involving the use of adenoviral vectors for cancer (Introgen Therapeutics Inc., USA Gencell Asia/Pacific, Japan) and DNA plasmid vectors for peripheral artery occlusive disease (Aventis Pharma, France/USA). Dr. Merzouki has an extensive expertise in the design of expressing vectors, production and purification of recombinants proteins. He developed technologies (Patents pending) for production of biogeneric therapeutic proteins for the treatment of various diseases including cancer, diabetes, hepatitis or multiple sclerosis," stated Dr. Max Arella, CEO and Chairman of Spencer Pharmaceutical Inc. "We are pleased that Dr. Merzouki has accepted to serve Spencer Pharmaceutical as a scientific and business advisor. His extensive network in scientific and businesses circles in the Middle East/North Africa regions will certainly be a major asset for our company in future negotiations in this part of the world," concluded Dr. Arella.
About Spencer Pharmaceutical Inc.
Spencer Pharmaceutical Inc. is a US based Pharmaceutical Research and Development Corporation, which is developing innovative drug release and absorption systems for the treatment of metabolic diseases such as diabetes and metabolic syndrome.
Spph :
Spencer Pharmaceutical Inc. Announces Dr. Abderrazzak Merzouki Joins the Scientific Advisory Board and Business Advisor
BOSTON, MA--(Marketwire - 10/28/10) - Spencer Pharmaceutical Inc. (Pinksheets:SPPH - News) announced today the addition of Dr. Abderrazzak Merzouki to join its Scientific Advisory Board as well as accepting a position as a business advisor with the company.
The management of Spencer Pharmaceutical Inc. is delighted to announce the addition of Dr. Merzouki to the Scientific Advisory Board. He brings a wealth of scientific research knowledge to the team. Dr. Merzouki is a research scientist and professor of Virology-Immunology.
Spencer Pharmaceutical Inc. Announces Dr. Abderrazzak Merzouki Joins the Scientific Advisory Board and Business Advisor
BOSTON, MA--(Marketwire - 10/28/10) - Spencer Pharmaceutical Inc. (Pinksheets:SPPH - News) announced today the addition of Dr. Abderrazzak Merzouki to join its Scientific Advisory Board as well as accepting a position as a business advisor with the company.
The management of Spencer Pharmaceutical Inc. is delighted to announce the addition of Dr. Merzouki to the Scientific Advisory Board. He brings a wealth of scientific research knowledge to the team. Dr. Merzouki is a research scientist and professor of Virology-Immunology.
Spencer Pharmaceutical Inc. Announces Dr. Abderrazzak Merzouki Joins the Scientific Advisory Board and Business Advisor
BOSTON, MA--(Marketwire - 10/28/10) - Spencer Pharmaceutical Inc. (Pinksheets:SPPH - News) announced today the addition of Dr. Abderrazzak Merzouki to join its Scientific Advisory Board as well as accepting a position as a business advisor with the company.
up and running green here very nice so far.
spph
AUSTIN, Texas--(BUSINESS WIRE)-- SmallCapVoice.com, Inc. announced today that a new audio interview featuring Spencer Pharmaceutical Inc. (Pinksheets:SPPH) is now available. The interview can be heard here http://smallcapvoice.com/blog/10-22-10-audio-interview-with-spencer-pharmaceutical-inc-pink-sheets-spph.
SmallCapVoice.com is a recognized corporate investor relations firm, with clients nationwide, known for its ability to help emerging growth companies build a following among retail and institutional investors. SmallCapVoice.com utilizes its stock newsletter to feature its daily stock picks, audio interviews, as well as its clients' financial news releases. SmallCapVoice.com also offers individual investors all the tools they need to make informed decisions about the stocks they are interested in. Tools like stock charts, stock alerts, and client information sheets can assist with investing in stocks that are traded on the OTC BB and Pink Sheets. To learn more about SmallCapVoice.com and their services, please visit http://www.smallcapvoice.com/services.html.
About Spencer Pharmaceutical Inc.
Spencer Pharmaceutical Inc. is a US-based Pharmaceutical Research and Development Corporation, which is developing innovative drug release and absorption systems for the treatment of metabolic diseases such as diabetes and metabolic syndrome.
About Spencer Pharmaceutical Inc.
Spencer Pharmaceutical Inc. is a US-based Pharmaceutical Research and Development Corporation, which is developing innovative drug release and absorption systems for the treatment of metabolic diseases such as diabetes and metabolic syndrome.
still nice support holding its value and hopefully we will see greens soon
About The International council for Corporate Governance:
The International Council for Corporate Governance is an International membership organization that provides publicly traded companies with a practice model for Corporate Governance Disclosure. Their goal is to increase the standard of corporate transparency and corporate governance disclosure to increase investor confidence. For more information please visit: www.i2cg.org
i agree, and so far the charts are holding on. could see a move or bounce soon. we have the potential to do so.
SPPH :
According to management, the company has signed confidentiality agreements with several companies and has begun talks over the distribution and formulations of its MET4 and Ibuprofen formulations as well as the co-development of several new formulations. The company expects to be in a position to sign a memorandum of understanding and or licensing agreements on or before February 10, 2011.
"Our formulation is very easy to manufacture compared to existing formulations, in addition to being better for the patient therefore making the MET4 ideal for licensing," said Dr. Max Arella, President of Spencer Pharmaceutical Inc. "The licensing for our Met4 to these companies could yield substantial financial results in the very short term for our company and can be the driving force in making Spencer a world class pharmaceutical," further added Dr. Arella.
About Spencer Pharmaceutical Inc.
Spencer Pharmaceutical Inc. is a US-based Pharmaceutical Research and Development Corporation, which is developing innovative drug release and absorption systems for the treatment of metabolic diseases such as diabetes and metabolic syndrome.
Our formulation is very easy to manufacture compared to existing formulations, in addition to being better for the patient therefore making the MET4 ideal for licensing," said Dr. Max Arella, President of Spencer Pharmaceutical Inc. "The licensing for our Met4 to these companies could yield substantial financial results in the very short term for our company and can be the driving force in making Spencer a world class pharmaceutical," further added Dr. Arella.
0.32 ? -0.005 (-1.54%)
Volume: 5,100 @ 10:36:43 AM ET
Bid Ask Day's Range
0.26 0.32 0.31 - 0.32
lets get the greens here soon.
Volume: 83,980 @ 12:09:55 PM ET
Bid Ask Day's Range
0.2501 0.3289 0.24 - 0.33
Full SPPH Quote
holding strong
SPPH
AUSTIN, Texas--(BUSINESS WIRE)-- SmallCapVoice.com, Inc. announced today that a new audio interview featuring Spencer Pharmaceutical Inc. (Pinksheets:SPPH) is now available. The interview can be heard here http://smallcapvoice.com/blog/10-22-10-audio-interview-with-spencer-pharmaceutical-inc-pink-sheets-spph.
SmallCapVoice.com is a recognized corporate investor relations firm, with clients nationwide, known for its ability to help emerging growth companies build a following among retail and institutional investors. SmallCapVoice.com utilizes its stock newsletter to feature its daily stock picks, audio interviews, as well as its clients' financial news releases. SmallCapVoice.com also offers individual investors all the tools they need to make informed decisions about the stocks they are interested in. Tools like stock charts, stock alerts, and client information sheets can assist with investing in stocks that are traded on the OTC BB and Pink Sheets. To learn more about SmallCapVoice.com and their services, please visit http://www.smallcapvoice.com/services.html.
About Spencer Pharmaceutical Inc.
Spencer Pharmaceutical Inc. is a US-based Pharmaceutical Research and Development Corporation, which is developing innovative drug release and absorption systems for the treatment of metabolic diseases such as diabetes and metabolic syndrome.
"It was found that our excipient was able to formulate small-size molecules either polar (hydrophilic such as metformin or ibuprofen) or non polar (as acetaminophen) as well as medium or large-size molecules such as bioactive peptides (ex. Nisin), proteins or even microorganisms (probiotics), essentially applying to many popular Over the Counter drugs and prescribed as well," stated Dr. Max Arella, CEO of the company.
However many of the delivery technologies for therapeutic peptides or proteins failed to overcome three major obstacles: i) Denaturation of the peptide or of the protein or bacterium by gastric acid and even by pepsin protease in the stomach environment, ii) Degradation of the peptide or protein or bacterium by the attack of proteolytic enzymes in intestine, iii) poor or limited absorption of the peptide or protein into the bloodstream (if not directed to the colon).
Volume: 60,680
Bid Ask Day's Range
0.25 0.2999 0.24 - 0.33
lets brake the days range
SPPH :
interview can be heard here
http://smallcapvoice.com/blog/10-22-10-audio-interview-with-spencer-pharmaceutical-inc-pink-sheets-spph.
SPPH :
According to management, the company has signed confidentiality agreements with several companies and has begun talks over the distribution and formulations of its MET4 and Ibuprofen formulations as well as the co-development of several new formulations. The company expects to be in a position to sign a memorandum of understanding and or licensing agreements on or before February 10, 2011.
"Our formulation is very easy to manufacture compared to existing formulations, in addition to being better for the patient therefore making the MET4 ideal for licensing," said Dr. Max Arella, President of Spencer Pharmaceutical Inc. "The licensing for our Met4 to these companies could yield substantial financial results in the very short term for our company and can be the driving force in making Spencer a world class pharmaceutical," further added Dr. Arella.
About Spencer Pharmaceutical Inc.
Spencer Pharmaceutical Inc. is a US-based Pharmaceutical Research and Development Corporation, which is developing innovative drug release and absorption systems for the treatment of metabolic diseases such as diabetes and metabolic syndrome.
Our formulation is very easy to manufacture compared to existing formulations, in addition to being better for the patient therefore making the MET4 ideal for licensing," said Dr. Max Arella, President of Spencer Pharmaceutical Inc. "The licensing for our Met4 to these companies could yield substantial financial results in the very short term for our company and can be the driving force in making Spencer a world class pharmaceutical," further added Dr. Arella.
chart looks like we could be seeing a move here soon, 60k volume and staying at a nice rate.
According to management, the company has signed confidentiality agreements with several companies and has begun talks over the distribution and formulations of its MET4 and Ibuprofen formulations as well as the co-development of several new formulations. The company expects to be in a position to sign a memorandum of understanding and or licensing agreements on or before February 10, 2011.